Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Depth (Part 1): Guo Guangchang is holding hands with the originator of surgical robots in the world. Behind it is a big chess game that goes deep into the entire industry chain of AI, precision medicine, and health.
Category:
Trade info
Author:
Source:
Add time:2016-12-15 21:45
News background: In September 2016, Fosun Pharma announced the establishment of a joint venture in Shanghai with a wholly-owned subsidiary of Intuitive Surgical of the United States, with a joint capital injection of 100 million US dollars, mainly for research and development, production and sales of early diagnosis and treatment of lung cancer. product.
The editor has worked hard and in-depth long story,
In 10 minutes, let you understand Fosun's big game of deepening the AI, precision medicine and big health industry chain!
(Part 1)
1. Keyword 1: Intuitive Surgical
2. Keyword 2: Early diagnosis and treatment of lung cancer
3. Keyword three: R&D, production and sales
4. Keyword four: AI artificial intelligence
(Part 2) Stay tuned……
5. Fosun Pharma’s medical device segment layout ideas
6. Fosun Pharma Medical's entire industrial chain picture
7. Fosun General Health “Ecosphere”
On December 10, Fosun Pharma held the "Press Conference on Strategic Cooperation between Fosun Pharma and Intuitive Surgical of the United States and Artificial Intelligence-Assisted Precision Medicine Summit Forum" in Shanghai Ruijin Hotel.
In addition to Chen Qiyu, Chairman of Fosun Pharma, Guo Guangchang, Chairman of Fosun Group and non-executive director of Fosun Pharma, also visited the site and delivered a speech, which shows that Fosun’s senior management attaches great importance to the project. Also present at the scene was Dr. Gary Guthart, CEO of Intuitive Surgical, USA. This is also his first visit to China.
This mathematician with a "Jobs" style is Dr. Gary
On the same day, Huang Hong, Secretary of the Shanghai Municipal Health and Family Planning Commission, Xu Lai, Deputy Director of the Food and Drug Administration, Zhao Zilin, Chairman of the Chinese Medical Equipment Association, Wang Longxing, Chairman of the Shanghai Pharmaceutical Association, Gao Changqing, Academician of the 301 Hospital of the Chinese People's Liberation Army, China Lung Cancer Prevention Alliance The chairman, Professor Bai Chunxue, director of the Shanghai Institute of Respiratory Diseases, etc. were also all present. It can be described as a gathering of big names in industry, academia and research.
-
Why can a company's press conference attract big names from all walks of life?
-
Who is Intuitive Surgical?
-
What does it mean to establish a joint venture?
-
What is the current status of the early diagnosis and treatment products for lung cancer that it is concerned about?
-
Behind Guo Guangchang's visit to the scene, what is the big game of Fosun's big health “ecosphere”?
The editor will explain in detail one by one for you~~
Keyword one:Intuitive Surgical
First of all, the cooperative company Intuitive Surgical itself is very unusual: this company, which has been established for only 21 years and employs only more than 3,000 people, now has a market value of nearly 25 billion U.S. dollars on the Nasdaq, and its share price has changed from per share. 7 US dollars rushed to more than 700 US dollars per share. Especially in the current severe situation of US stocks, many pharmaceutical giants have suffered a slump in the stock price, but this company still maintains a stock price of more than $600, which is amazing.
The picture shows the stock price trend of Intuitive Surgical on December 12, 2016 Beijing time
The most important reason for supporting its stock price, in Chen Qiyu’s words, is because “Technically, Intuitive Surgical is very rare in the global medical device industry. So far, it has been relying on one product to reach a market value of 25 billion U.S. dollars, and it still maintains a rapid growth every year. The core of this company is that they insist on focusing on one point of innovation, and achieve this point of innovation to the extreme. The company has now authorized and applied for more than 4,000 patents, all of which are focused on one point. For so many years, competitors have wanted to do it, so far no one can really shake their core position. ”
So what is the core point? It is the "Da Vinci" minimally invasive robotic surgery system. The main appearance is as follows, so in fact, many people don’t know the official name of Intuitive Surgical, and they directly call this company "Da Vinci". In fact, "Da Vinci" is its main product, and it is also the product that it focused on before. 
The Da Vinci surgical robot is currently the most advanced minimally invasive surgical system in the world. It consists of three parts: an ergonomically designed doctor operating system, 3 instrument arms and 1 lens 4-arm bedside robotic arm system, high-definition three-dimensional video imaging system composed of arms
To put it simply, the Da Vinci robot is an advanced laparoscopic system. The FDA has approved the Da Vinci robotic surgery system for general surgery, thoracic surgery, urology, obstetrics and gynecology, head and neck surgery, and heart surgery for adults and children. The specific advantages of this system application are a major advancement in medical treatment from the perspective of patients and doctors.
You can imagine that a traditional operation requires a laparotomy, which is a crippling matter. And if a lung cancer patient can choose the Da Vinci robot, he can just make a few small holes and go out after a few days of surgery. This is the meaning of “Minimally Invasive Robot”.
Compared to traditional surgery, the robotic arm of the Da Vinci surgical robot can completely imitate the movements of the human wrist, and filter out the jitter of the hand, with stability and accuracy that human hands cannot match. Its range of motion is even much larger than that of a human hand, and it can freely move 360 degrees in a narrow anatomical area, and is more flexible than a human hand. At the same time, the Da Vinci surgical robot allows doctors to have a surgical field of vision consistent with the effect of open direct vision, ensuring hand-eye coordination. The high-resolution stereo cavity mirror provides high-definition three-dimensional images magnified 20 times, reducing the incidence of errors. For patients, the Da Vinci surgical robot can significantly improve the surgical effect, significantly reduce postoperative complications, injuries and blood loss, recover faster, shorten the hospital stay, and significantly improve the surgical effect and aesthetics. 
Surgeons know that Da Vinci is the only way for future surgery. Compared with laparoscopic technology, it can be said to be the difference between "rifle" and "machine gun". Nowadays, Da Vinci is very common in the United States. Hospitals in all 50 states are using Da Vinci surgical robots. High-end hospitals have almost full coverage. As of 2015, more than 3 million Da Vinci surgeries have been performed worldwide. About two-thirds of them are in the United States, and nearly 25,000 American doctors have received systematic training in Da Vinci surgery.
Interested students can directly click on the video to view the "Digital Interpretation" version of Intuitive Surgical Company to understand the overall situation of the company.
It is not an exaggeration to describe the Da Vinci robot with the "revolutionary and innovative technology in surgery". No wonder the capital market is so popular with it. However, the establishment of a joint venture between Fosun Pharma and it means that in the future, it is possible to innovate, develop and manufacture such a leading, next-generation medical technology in Shanghai.
At the press conference on December 10, Chairman Guo Guangchang personally experienced a "Da Vinci" robotic surgery system.
Moreover, a live broadcast of the "Da Vinci" robot charity surgery performed by Professor Chenghong Peng from Ruijin Hospital was also broadcast in real time. The scene cut into the main venue in real time, which gave the audience a very shocking experience. This is a pancreaticoduodenectomy, which requires simultaneous removal of the pancreatic head, bile duct, gallbladder, duodenum, stomach and other organs. The operation involves many organs and the surrounding blood vessels are interlaced. It is the most complicated and difficult general surgery operation. One of the operations. In the end, under the common witness of the audience, Professor Peng skillfully operated the "Da Vinci" robot and completed the operation perfectly!
Keyword 2: Lung cancerEarly diagnosis andTreatment >
There are actually two keywords here, "lung cancer" and "early diagnosis and treatment".
First of all, about "lung cancer". According to the introduction of Professor Bai Chunxue, chairman of the China Association for Lung Cancer Prevention and Treatment and Director of the Shanghai Institute of Respiratory Diseases, an authoritative expert on the scene: "From a global perspective, the mortality rate of lung cancer is the highest among men and women. In fact, the highest incidence of women is not lung cancer, but breast cancer. Lung cancer is more dangerous to life. Looking at the data from Asia, Japan, South Korea, Thailand, and Taiwan are compared, and the incidence of lung cancer in China has become the highest in Asia. It is 70/100,000 for men and 36/100,000 for women. The five-year survival rate is lower. ”Lung cancer has become one of the most common malignant tumors in the world, and due to haze and other reasons, the situation in my country is particularly serious. According to the latest cancer statistics, lung cancer has become the country with the highest incidence and death rate. Cancer is a veritable "king of cancer".
The second keyword here is "early diagnosis and treatment". Why is early diagnosis and treatment so important? This is because the current diagnosis of lung cancer is basically late, which poses a huge threat to the five-year survival rate of patients.
From the chart shared by Dr. Gary on-site, it can be seen that if lung cancer can be diagnosed at an early stage, it will significantly improve the 5-year survival rate of patients.
The study found that the 5-year survival rate depends on the stage of lung cancer diagnosis, that is, the size of the tumor. If the tumor is confirmed in the first stage and the tumor size is less than 3 cm, the corresponding 5-year survival rate will reach 73%, and the 5-year survival rate in the second stage will be 58%. By the fourth stage, the 5-year survival rate will be 58%. The survival rate dropped to 36%. Obviously, the first stage tumor is the main target for breaking through the 5-year survival rate of lung cancer.
It is conceivable what this means for the patient and the patient’s family, and overcoming the "early diagnosis of lung cancer" technology has great social significance. Because of this, at the scene, Ms. Xu Lai, deputy director of the Shanghai Food and Drug Administration, said in her speech: “Our country has a green channel review, review and approval system for listing. There is an urgent need for clinical trials, especially for varieties with clinical advantages, to be included in the green channel and to adopt various methods for priority review. Since its implementation in 2014, a total of 77 varieties across the country have entered this green channel. Through the joint efforts of the industry and the government, a total of 13 varieties have entered the green channel. Fosun Pharma has also paid great attention to research and development and investment for a long time. We also wish this product can enter the green channel of the country and be listed as soon as possible to benefit the people. "It truly expresses the government's ardent hope and the society's huge real demand for this technology.
Keyword three:R&D, production and sales
If we say that the establishment of a "joint venture company" officially marks that the cooperation between Fosun Pharma and Intuitive Surgical has gone from agency to joint venture, and has reached a deeper and more stable stage. So it is undoubtedly more meaningful to locate the "R&D and manufacturing" centers in Shanghai. Dr. Gary said, "I hope that the Shanghai joint venture will be the second home of Intuitive Surgical". This is undoubtedly a sincere commitment to long-term cooperation. ”
The joint venture will develop and produce another brand-new innovative product in addition to the "Da Vinci" system. This time, it will use the "Made in China, joint research and development, and global sales" model. According to Gary: “The first project of the joint venture company will be to develop and manufacture a product based on robot-assisted catheter technology. This system has not yet been commercialized in any market in the world. Therefore, the commercialization of the product may be completed in China first, or completed simultaneously in China and the world. ”The world's most advanced robot-assisted lung cancer early diagnosis product will probably be born in China first, which will be a great encouragement to China's entire “innovation” strategy!
In the current environment, we are committed to solvingTechnological innovation in difficult early diagnosis of lung cancer, and setting up the joint venture factory in Shanghai, can be said to be a "time, place, people and" thing, which is also a point mentioned by many leaders at the conference.
Professor Bai Chunxue said:“Now we are the fourth industrial revolution, and we have encountered such a good environment with the right time and place. Not only did we participate in the run, we also want to lead the race. At least in the Asia-Pacific countries, we are a leader in the field of early diagnosis of lung cancer. We have the right time and place, and our top-level design, academic leadership, and technological innovation are recognized in Asia-Pacific countries. We have policy support, huge demand and the support from everyone, which is very good. I believe it is time for us to do great things in the prevention and treatment of lung cancer. ”
Zhao Zilin, Chairman of the China Medical Equipment Association, also mentioned in his speech at the scene: "In recent years, China has attached great importance to the development of medical devices, actively encouraged overseas mergers and acquisitions, equity investment, and paid attention to new products and key technologies. At the same time, it encourages the establishment of R&D centers and procurement centers in China. In addition, Shanghai is China's economic center and financial center, with strong talents and technologies. Your cooperation is a strong cooperation, and the project will definitely develop rapidly. ”
In addition to "joint research and development", "Made in China" is of course also a bright spot. All along, the consideration of "cost" must be the most important point for the introduction of new technologies to the market. Therefore, the new company has also placed production in China. At the press conference, Chairman Chen Qiyu made a heartfelt promise: "We will also consider the burden of the entire society and patients. We will definitely find a balance between the burden of patients and the availability of products. A plan that everyone can accept. The most precious thing in the world is life, and affordability must be considered by joint ventures. ”
Keyword four:AI artificial intelligence
In the announcement issued by Fosun Pharma in September, there is also a detailed description: "The new company will be engaged in medical equipment, equipment, new products, future products and related parts and components for transcavitary surgery diagnosis and treatment. R&D, manufacturing and sales. It mainly develops, produces and sells products for the early diagnosis and treatment of lung cancer. This product uses patented and unique technologies with real-time video, radiographic image fusion, optical fiber precise positioning technology and intelligent robot navigation to quickly diagnose patient pathology and provide accurate treatment. ”
Among these, "intelligent robots" and "precision treatments" are particularly worthy of attention. In fact, this is one of the future development directions of Fosun Pharma that Chairman Chen Qiyu has always emphasized. At this press conference, Chen Qiyu said in an interview: “The application scenarios of artificial intelligence will be very extensive in the future. Let’s make an analogy: a good doctor we see now, such as a doctor from Ruijin Hospital, how did he come? What about? First of all, he must be excellent in his studies, enter the best university, and then get a Ph.D., and have the opportunity to stay in Ruijin Hospital, or to study a PhD abroad to have the opportunity to stay in the top hospitals and get in touch with the most complicated cases. . Then, continue to accumulate. When I reach the age of about 45, I will soon become an experienced doctor in my 40s, and then I will retire in my 60s. That is to say, the process that a good doctor goes through is learning, accumulation, and practice. In the end, various cases are comprehensively summarized in his mind. But after he reached a certain biological age, he had to leave the medical post. Therefore, the best doctors in the world are always one of the most scarce medical resources, because the process of accumulating knowledge and experience is a very complicated process that cannot be mastered by ordinary people. With deep learning and artificial intelligence, it can be accumulated through machine simulation, anthropomorphization, and learning capabilities similar to the human brain. The things it has learned continue to accumulate, and it does not need to retire, do not need to sleep, and it will continue forever. To learn, and can be copied. So I think In the future, artificial intelligence will become an important assistant to outstanding doctors in the medical field. This is an inevitable trend. The combination of artificial intelligence systems and good doctors forms a main body, which can greatly improve the accuracy of medical diagnosis and treatment, and can greatly improve the supply capacity of high-quality resources. At this point, it should be said that artificial intelligence in the medical field is all aspects and all aspects. ”
The chairman of Fosun Group Guo Guangchang also emphasized in his keynote speech: "This time we persuaded Gary to cooperate with us, not just to treat China as a market, not just to treat China as a factory. In fact, China, especially Shanghai, has very strong R&D capabilities. Therefore, we have to jointly develop the world's most advanced new generation of robots with the latest technology platform in Shanghai, and we must lead the world in this area. Simultaneous research and development, simultaneous global sales. This synchronization means simultaneous sales in China, but the research and development technology is a Chinese joint venture, rather than simply transferring the technology over from the United States. We want to form our own advanced and unique research and development in this field, which is to treat the joint venture as Intuitive Surgical in Shanghai. For the second home, we have to move the entire technology over. "This passage can be said to profoundly express Chairman Guo Guangchang's expectations and determination for precision medicine and artificial intelligence, especially his determination and confidence in building China's local R&D capabilities.
The academician Gao Changqing of the People's Liberation Army 301 Hospital who spoke at the meeting is a typical representative of "elite doctors" who use "artificial intelligence and robot-assisted precision medicine" to greatly improve clinical capabilities. Professor Gao said that he has worked in the clinical frontline for 30 years and performed more than 5,000 various heart surgeries. However, he believes that his main contribution is to create a precedent for robotic minimally invasive surgery in China, leading and promoting international robotic surgery. development of. From the first visit to Intuitive Surgical in 2006, Professor Gao felt that it was a "very amazing" company. After returning to China, Professor Gao used the Da Vinci robot to complete the first non-open chest operation on January 15, 2007, achieving a zero breakthrough nationwide. Since then, Professor Gao has always taken heart surgery without opening the chest as a lifelong dream, and has repeatedly performed operations that others have not done before.
Therefore, the editor on several key points of the press conference of the day has been interpreted for everyone here.
The "big chess game" of Fosun Health, Fosun Pharma in the medical device sector and even the entire medical industry chain reflected behind this has yet to be further interpreted.……
